Skip to main content

Table 1 Patient demographics and baseline characteristics, ITT population

From: Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support

Parameter

PVI

PIO

(n = 53)

(n = 57)

Age, y

30.9 (20–40)

31.5 (22–41)

BMI, kg/m2

26.9 (5.2)

28.9 (6.5)

Race

  

   White

38 (71.7)

43 (75.4)

   Black

0

1 (1.8)

   Asian

9 (17.0)

2 (3.5)

   Hispanic

6 (11.3)

10 (17.5)

   Other

0

1 (1.8)

Duration of infertility, months

32.2 (19.7)

49.6 (44.6)

 

26.0 (10–96)

34.0 (12–240)

ART History

  

   Number previous IVF cycles

0.2 (0.5)

0.2 (0.4)

   Number failed IVF cycles

0.1 (0.3)

0.1 (0.3)

   Number previous ovulation induction cycles*

4.2 (3.1)

5.3 (6.8)

   Number failed ovulation induction cycles

4.1 (3.1)

5.2 (6.8)

Gonadotropin for ovulation induction

  

   rFSH

28 (52.8)

30 (52.6)

   HP-hMG

25 (47.2)

27 (47.4)

  1. Values are n (%), median (range), or means (standard deviation).
  2. *Excluding IVF, gamete intrafallopian transfer, and/or pronuclear stage embryo transfer.
  3. Excluding IVF.
  4. ITT, intent to treat; PVI, progesterone vaginal insert; PIO, progesterone in oil; BMI, body mass index; ART, assisted reproductive technologies; rFSH, recombinant follicle-stimulating hormone; HP-hMG, highly purified human menopausal gonadotropin.